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Response
Drs Sughrue and Connolly correctly point out that the preclinical data indicate that UK-279,276 might potentially be protective against cerebral reperfusion injury but might not have neuroprotective properties in the absence of reperfusion. When designing ASTIN we did debate including measures of cerebral perfusion and decided against it, mainly for logistical reasons: perfusion CT was not yet widely available, and overcoming the technical issues related to establishing tight interrater reliability of transcranial Doppler measurements appeared a difficult challenge at the time. However, we entirely agree that quantifying the degree of perfusion and using it as a covariate of interest is the way to go in future acute stroke trial exploring compounds that show promise in reperfusion but not in permanent occlusion stroke models.
The alternative of limiting the patient population to intravenous tPA-treated patients was also discussed, with a goal to enrich the proportion of patients with reperfusion. However, from a sponsor perspective the objective was not to develop an adjuvant therapy to intravenous tPA but to establish a neuroprotective therapy that could benefit the overall set of patients with ischemic strokes including those who spontaneously reperfused. The proportion of spontaneous reperfusion within the first 6 hours has been described as 19% 1 ; ie, it seemed reasonable to allow inclusion of tPA-and non-tPA-treated patients.
Had we known prior to the start of ASTIN that Ͼ20% of patients would be cotreated with intravenous tPA rather than the Ͻ5% we anticipated, we would have probably designed a different trial. One interpretation of the mean improvement of 1.6 points on the Scandinavian Stroke Scale in the tPA-treated subset of 204 patients is that it is a pure tPA effect and has nothing to do with UK-279,276: ASTIN does not allow any conclusions about interactions between UK-279,276 and tPA.
Given the limitations of the ASTIN trial, it is important to remember that absence of evidence is not evidence of absence for the mechanism of action in an appropriately chosen patient population. An interesting future research question might be whether an adjuvant therapy to intravenous tPA apart from potentially improving outcome might also allow to reduce the overall dose of tPA and thereby potentially add safety benefits. We are currently developing designs that would allow the continuous reassessment of the exposure-response and adaptive allocation to the most promising treatment combination. 
